📰 RFK Jr to encourage Americans to use ‘wearable’ tech to track their health
U.S. Health Secretary Robert F. Kennedy Jr. expressed his vision that every American will be wearing a wearable device within four years, such as smartwatches and fitness trackers. He announced plans for a major advertising campaign by the Department of Health and Human Services to promote the use of wearables for health monitoring. Kennedy emphasized that wearables empower individuals to take control of their health by tracking metrics like glucose levels and heart rates. He highlighted success stories of people improving their health through wearable technology, leading to increased stock prices for companies like Abbott and Dexcom. Kennedy’s focus on promoting healthy lifestyles through wearables aligns with his criticism of traditional medicine and support for proactive health monitoring.
📰 New stem cell therapy shows ‘promising’ results for treating hair loss in preclinical trials
Researchers at the San Carlos Clinical Hospital in Madrid conducted a study on using adipose-derived stem cells (ASCs) from human fat to treat male- and female-pattern hair loss. Male mice showed the best hair regrowth after receiving low-dose ASCs and adenosine triphosphate (ATP), while females had greater regrowth with medium-dose ASCs plus ATP. The study, led by Dr. Eduardo López Bran, demonstrated significant hair regrowth in both male and female mice. The findings, published in Stem Cell Research & Therapy, suggest a potential new therapeutic approach for androgenetic alopecia. Dr. Bran emphasized the need for caution and further research before confirming clinical benefits in humans.
📰 Hepatitis A outbreak infects thousands of travelers at popular destinations
A spike in hepatitis A infections has affected thousands of travelers in popular European destinations, leading to several deaths. Austria, Czechia, Hungary, and Slovakia have collectively reported 2,097 cases between January and May 2025. The disease is mainly spread through contaminated food or water, or close contact with infected individuals. Hepatitis A is an acute viral liver disease caused by the hepatitis A virus, and it can cause serious illness. The ECDC recommends investigating means of transmission, targeted vaccination programs, post-exposure prophylaxis, genetic testing of the virus, and increased education and awareness among high-risk groups to address the outbreak. Vaccination or immune globulin within two weeks of exposure can prevent illness, and those who are not vaccinated or previously infected are susceptible to the virus.
📰 Single dose of ‘magic mushrooms’ provides 5 years of depression relief, researchers find
A new study presented at the Psychedelic Science 2025 conference in Denver revealed that psilocybin, the main psychoactive ingredient in magic mushrooms, could provide long-lasting relief from depression for up to five years after just one dose. The study followed up with patients diagnosed with major depressive disorder who had participated in a previous psilocybin treatment study in 2020. Results showed that most participants reported improvements in depression symptoms lasting for years. The study highlighted the potential of psilocybin and other psychedelic-based treatments in treating mental health conditions, with promising outcomes observed in previous trials. Researchers emphasized the need for further controlled studies to explore the extended efficacy of these treatments, while also acknowledging the importance of safe administration and monitoring during psychedelic therapy sessions.
📰 Experimental drug helps patients lose nearly a quarter of body weight in early trials
An experimental weight-loss medication called amycretin, developed by Novo Nordisk, was found to help participants lose up to 24.3% of their body weight in early-stage trials by replicating hunger hormones amylin and GLP-1. The drug was shown to be more effective than a placebo in promoting weight loss in overweight or obese adults, with the highest doses leading to the most significant weight reduction. Previous trials of the oral version of amycretin also demonstrated safety and tolerability, with participants experiencing weight loss compared to those on a placebo. People taking amycretin did not seem to hit a weight-loss plateau, suggesting the potential for further weight reduction with extended treatment. Common side effects of amycretin, like other GLP-1s, included gastrointestinal symptoms, and researchers emphasized the need for close monitoring due to the prevalence of GI issues in patients with obesity. Novo Nordisk plans to advance both subcutaneous and oral versions of amycretin into phase 3 development for weight management, acknowledging the need for further studies to assess long-term benefits and risks.
0개의 댓글